Ovarian morphology and function during growth hormone therapy of short girls born small for gestational age Jeanette Tinggaard, M.D., Rikke Beck Jensen,

Slides:

Advertisements

Similar presentations

Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States David B. Seifer, M.D., Valerie.

Advertisements

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Longitudinal assessment of circulating insulin-like peptide 3 levels in healthy peripubertal girls Casper P. Hagen, Ph.D., Mikkel G. Mieritz, M.D., John.

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice Laura Detti, M.D., Rebecca A. Uhlmann,

Variation in circulating antimüllerian hormone precursor during the periovulatory and acute postovulatory phases of the human ovarian cycle Michael W.

Developmental programming: prenatal testosterone excess disrupts anti-Müllerian hormone expression in preantral and antral follicles Almudena Veiga-Lopez,

Longitudinal assessment of circulating insulin-like peptide 3 levels in healthy peripubertal girls Casper P. Hagen, Ph.D., Mikkel G. Mieritz, M.D., John.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study Thi.

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues,

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study

Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M

Antimüllerian hormone levels decrease in women using combined contraception independently of administration route Sanna Kallio, M.D., Johanna Puurunen,

Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression

Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.

A comparison of blood spot vs

Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency Carrie.

Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause Chris M.G. Thomas, Ph.D.,

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

Mikkel Rosendahl, M. D. , Claus Yding Andersen, D. M. Sc

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Uterine volume and endometrial thickness in healthy girls evaluated by ultrasound (3- dimensional) and magnetic resonance imaging Casper P. Hagen, M.D.,

Growth hormone, insulin-like growth factor I, and leptin interaction in human cultured lutein granulosa cells steroidogenesis Maria Karamouti, M.D, Panagoula.

Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH) P. Barriere, T. Freour, D. Masson,

Pregnancy-associated plasma protein A in human ovarian follicles and its association with intrafollicular hormone levels Jane Alrø Bøtkjær, M.Sc., Janni.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

Robert F. Casper, M.D. Fertility and Sterility

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.

Circulating antimüllerian hormone levels in boys decline during early puberty and correlate with inhibin B Matti Hero, M.D., Ph.D., Johanna Tommiska,

Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection Dorothea M.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

MaryFran Sowers, Ph. D. , Daniel McConnell, Ph. D

Effect of first line cancer treatment on the ovarian reserve and follicular density in girls under the age of 18 years Meryam El Issaoui, M.D., Veronica.

Effects of growth hormone and insulin-like growth factor 1 on progesterone production in human luteinized granulosa cells Toshiaki Taketani, M.D., Yoshiaki.

Antecubital vein venous sampling does not distort circulating levels of peptide and sex steroid hormones Michael P. Diamond, M.D., Michael Kruger, M.S.,

FSHB-211 and FSHR 2039 are associated with serum levels of follicle-stimulating hormone and antimüllerian hormone in healthy girls: a longitudinal cohort.

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.

Paolo Moghetti, M.D. Fertility and Sterility

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Insulin growth factors may be implicated in human sperm capacitation

Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist Casper P. Hagen, M.D., Kaspar Sørensen,

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

Direct injection of vascular endothelial growth factor into the ovary of mice promotes follicular development Ramiro Quintana, M.D., Laura Kopcow, M.D.,

A new era in ovulation induction

Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation

The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism.

Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D

Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development

Ovarian follicular volume and follicular surface area are better indicators of follicular growth and maturation, respectively, than is follicular diameter

Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.

Presentation transcript:

Ovarian morphology and function during growth hormone therapy of short girls born small for gestational age Jeanette Tinggaard, M.D., Rikke Beck Jensen, M.D., Ph.D., Karin Sundberg, D.M.Sc., Niels Birkebæk, M.D., Ph.D., Peter Christiansen, M.D., Annie Ellermann, M.D., Kirsten Holm, M.D., Ph.D., Eva Mosfeldt Jeppesen, M.D., Ph.D., Britta Kremke, M.D., Pawel Marcinski, M.D., Ph.D., Carsten Pedersen, M.D., Nina Saurbrey, M.D., Ebbe Thisted, M.D., Katharina M. Main, M.D., Ph.D., Anders Juul, D.M.Sc., Ph.D. Fertility and Sterility Volume 102, Issue 6, Pages 1733-1741 (December 2014) DOI: 10.1016/j.fertnstert.2014.09.014 Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Circulating serum levels of IGF-I (top) and IGFBP-3 (bottom) according to age during GH therapy in 18 short prepubertal SGA girls. Blue lines represent high-dose regimen (67 μg/kg/day); red lines represent low-dose regimen (35 μg/kg/day); and green lines represent IGF-I-titrated regimen. Solid black lines represent mean ±2 SD. Dotted black lines represent the lowest detection limit (20). GH = growth hormone; IGF = insulin-like growth factor; IGFBP = insulin-like growth factor binding protein; SGA = small for gestational age. Fertility and Sterility 2014 102, 1733-1741DOI: (10.1016/j.fertnstert.2014.09.014) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Circulating serum levels of FSH, LH, estradiol, AMH, Inhibin A, Inhibin B, testosterone, and SHBG according to age during GH therapy in 18 short, prepubertal, SGA girls. Solid blue lines represent mean ±2 SD and dotted black lines represent detection limit (15–19). One girl who presented with precocious puberty is highlighted in pink with filled squares before and blank squares after treatment with a GnRH agonist. AMH = anti-Müllerian hormone; FSH = follicle-stimulating hormone; GH = growth hormone; GnRH = gonadotropin-releasing hormone; LH = luteinizing hormone; SGA = small for gestational age; SHBG = sex hormone binding globulin. Fertility and Sterility 2014 102, 1733-1741DOI: (10.1016/j.fertnstert.2014.09.014) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Volume of uterus (top), ovaries (middle), and follicular size (bottom) according to age during GH therapy in 18 short, prepubertal, SGA girls. Solid blue lines represent mean ± 2 SD; dotted blue lines represent ±1 SD (21). One girl who presented with precocious puberty is highlighted in pink with filled squares before and blank squares after treatment with a GnRH agonist. GH = growth hormone; GnRH = gonadotropin-releasing hormone; SGA = small for gestational age. Fertility and Sterility 2014 102, 1733-1741DOI: (10.1016/j.fertnstert.2014.09.014) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions